30 Sept 2026, 12:56
Capital RaisingMS
CYPCYNATA THERAPEUTICS LIMITED
Announcement history available from 1 August 2025
Fromto
30 Sept 2026, 08:28
Meetings & Governance—
28 Sept 2026, 17:24
Company Administration—
28 Sept 2026, 17:24
Company Administration—
28 Sept 2026, 17:24
Financial Results—
24 Sept 2026, 09:29
Periodic ReportsMS
11 Sept 2026, 08:22
Securities Administration—
31 Aug 2026, 10:07
Financial ResultsMS
25 Aug 2026, 17:50
Securities Administration—
30 July 2026, 11:02
Quarterly ReportsMS
10 July 2026, 08:38
Securities Administration—
6 July 2026, 08:37
Director Interests—
6 July 2026, 08:35
Capital RaisingMS
2 July 2026, 18:31
Substantial Holders—
2 July 2026, 08:15
Substantial Holders—
30 June 2026, 08:57
Substantial Holders—
23 June 2026, 15:47
Substantial Holders—
22 June 2026, 08:19
Presentations—
19 June 2026, 09:22
ReinstatementMS
19 June 2026, 09:22
Company UpdateMS
17 June 2026, 12:05
Company UpdateMS
16 June 2026, 08:53
Trading Halt / SuspensionMS
12 June 2026, 09:46
Trading Halt / SuspensionMS
3 June 2026, 08:48
Company UpdateMS
29 May 2026, 08:56
Company Update—
27 May 2026, 08:54
Company Update—
8 May 2026, 09:01
Securities Administration—
8 May 2026, 08:57
Securities Administration—
4 May 2026, 09:05
Securities Administration—
4 May 2026, 09:05
Capital RaisingMS
30 Apr 2026, 10:00
Quarterly ReportsMS
30 Apr 2026, 09:03
Trading Halt / SuspensionMS
7 Apr 2026, 08:31
Securities Administration—
30 Mar 2026, 08:58
Company UpdateMS
26 Feb 2026, 15:43
Financial ResultsMS
5 Feb 2026, 09:29
Presentations—
4 Feb 2026, 09:05
Presentations—
29 Jan 2026, 09:30
Quarterly ReportsMS
23 Jan 2026, 17:41
Securities AdministrationMS
15 Dec 2025, 09:09
Company UpdateMS
4 Dec 2025, 08:56
Company UpdateMS
1 Dec 2025, 08:48
Director Interests—
1 Dec 2025, 08:46
Director Interests—
1 Dec 2025, 08:45
Director Interests—
1 Dec 2025, 08:39
Securities Administration—
24 Nov 2025, 09:24
Company UpdateMS
17 Nov 2025, 08:53
Presentations—
13 Nov 2025, 11:37
Meetings & Governance—
13 Nov 2025, 08:22
Presentations—
6 Nov 2025, 08:54
Presentations—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 30 Sept 2026, 12:56 | R&D Tax Incentive Loan Facility Extension | Capital Raising | MS | 03022, 11001 | |
| 30 Sept 2026, 08:28 | Date of AGM and Closing Date for Director Nominations | Meetings & Governance | — | 08006 | |
| 28 Sept 2026, 17:24 | Appendix 4G | Company Administration | — | 03025 | |
| 28 Sept 2026, 17:24 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 28 Sept 2026, 17:24 | Annual Report | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 24 Sept 2026, 09:29 | Notification under Listing Rule 4.3D | Periodic Reports | MS | 03014, 12008 | |
| 11 Sept 2026, 08:22 | Notification of cessation of securities - CYP | Securities Administration | — | 06027 | |
| 31 Aug 2026, 10:07 | Appendix 4E & Preliminary Final Report | Financial Results | MS | 03003 | |
| 25 Aug 2026, 17:50 | Proposed issue of securities - CYP | Securities Administration | — | 06013 | |
| 30 July 2026, 11:02 | June 2026 Quarterly Activity Report & Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 10 July 2026, 08:38 | Notification of cessation of securities - CYP | Securities Administration | — | 06027 | |
| 6 July 2026, 08:37 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 6 July 2026, 08:35 | Board, Management Changes, Expenditure Reductions, RDTI Loan | Capital Raising | MS | 03022, 12001, 12008, 12019 | |
| 2 July 2026, 18:31 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 2 July 2026, 08:15 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 30 June 2026, 08:57 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 23 June 2026, 15:47 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 22 June 2026, 08:19 | Investor Webinar | Presentations | — | 03026, 14014 | |
| 19 June 2026, 09:22 | Reinstatement to Official Quotation | Reinstatement | MS | 09002 | |
| 19 June 2026, 09:22 | CYP-004 Osteoarthritis Trial Results | Company Update | MS | 11001, 14014 | |
| 17 June 2026, 12:05 | CYP-001 GvHD Trial Primary Evaluation Results | Company Update | MS | 11001 | |
| 16 June 2026, 08:53 | Suspension from Quotation | Trading Halt / Suspension | MS | 09001 | |
| 12 June 2026, 09:46 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 3 June 2026, 08:48 | EU Positive Opinion on CYP-001 Paediatric Investigation Plan | Company Update | MS | 11001 | |
| 29 May 2026, 08:56 | WHO Selects Proposed INN for Cymerus MSCs | Company Update | — | 11001 | |
| 27 May 2026, 08:54 | Expected Timing of Clinical Trial Results | Company Update | — | 11001 | |
| 8 May 2026, 09:01 | Cleansing Notice | Securities Administration | — | 06018 | |
| 8 May 2026, 08:57 | Application for quotation of securities - CYP | Securities Administration | — | 06020 | |
| 4 May 2026, 09:05 | Proposed issue of securities - CYP | Securities Administration | — | 06013 | |
| 4 May 2026, 09:05 | Cynata Secures Commitments for $1.5m Placement | Capital Raising | MS | 03026, 06003, 09014 | |
| 30 Apr 2026, 10:00 | March 2026 Quarterly Activity Report & Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 30 Apr 2026, 09:03 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 7 Apr 2026, 08:31 | Notification of cessation of securities - CYP | Securities Administration | — | 06027 | |
| 30 Mar 2026, 08:58 | Last Visit in GvHD Trial Completed | Company Update | MS | 11001 | |
| 26 Feb 2026, 15:43 | Appendix 4D & Half-Year Financial Statements | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 5 Feb 2026, 09:29 | Cynata to Present at 2026 Euroz Hartleys Healthcare Forum | Presentations | — | 03026 | |
| 4 Feb 2026, 09:05 | Investor Webinar | Presentations | — | 03026, 14014 | |
| 29 Jan 2026, 09:30 | December 2025 Quarterly Activity Report and Appendix 4C | Quarterly Reports | MS | 19002, 19007 | |
| 23 Jan 2026, 17:41 | Cynata Completes $1.2m At-The-Market Raise | Securities Administration | MS | 06009 | |
| 15 Dec 2025, 09:09 | Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial | Company Update | MS | 11001 | |
| 4 Dec 2025, 08:56 | Positive DSMB Review in Phase 1/2 Kidney Transplant Trial | Company Update | MS | 11001 | |
| 1 Dec 2025, 08:48 | Appendix 3Y - Dr Paul Wotton | Director Interests | — | 02009 | |
| 1 Dec 2025, 08:46 | Appendix 3Y - Dr Darryl Maher | Director Interests | — | 02009 | |
| 1 Dec 2025, 08:45 | Appendix 3Y - Dr Geoff Brooke | Director Interests | — | 02009 | |
| 1 Dec 2025, 08:39 | Notification of cessation of securities - CYP | Securities Administration | — | 06027 | |
| 24 Nov 2025, 09:24 | Final Patient Visit Complete in Phase 3 Osteoarthritis Trial | Company Update | MS | 11001 | |
| 17 Nov 2025, 08:53 | Investor Presentation | Presentations | — | 03026 | |
| 13 Nov 2025, 11:37 | Results of Annual General Meeting | Meetings & Governance | — | 08003 | |
| 13 Nov 2025, 08:22 | AGM Presentations | Presentations | — | 03026, 15002 | |
| 6 Nov 2025, 08:54 | Investor Webinar | Presentations | — | 03026, 14014 |
1–50 of 64
1 / 2